Increased levels of lipid peroxidation products malondialdehyde and 4-hydroxynonenal after perinatal hypoxia.
For quantitative evaluation of lipid peroxidation after perinatal hypoxia in umbilical arterial cord blood samples from 109 healthy, acidotic, and asphyctic neonates with a gestational age ranging from 26 to 41 wk, the levels of aldehydic lipid peroxidation products malondialdehyde (MDA) and 4-hydroxynon-2-enal (HNE) were measured. Furthermore, the concentrations of oxidized and reduced glutathione (GSSH and GSH) and the purine compounds hypoxanthine and uric acid were determined. With increasing gestational age MDA and HNE levels increased. Furthermore, an increased level of GSH was also found. After perinatal hypoxia the concentrations of MDA and HNE rose distinctly (p < 0.001), reflecting sensitively the extent of in vivo lipid peroxidation. HNE is proposed to be a new parameter for quantitative evaluation of posthypoxic cellular damage in the perinatal period. HNE is a more specific parameter for estimation of lipid peroxidation processes in comparison with MDA. Additionally, HNE is cytotoxic and mutagenic at nanomolar concentrations. The increased levels of both MDA and HNE were accompanied by a strong decrease of GSH concentrations (p < 0.001), indicating the rapid consumption of GSH via a glutathione peroxidase reaction but additionally the high reactivity of HNE with sulfhydryl groups. During oxygen deficiency, increased levels of hypoxanthine (p < 0.01) and uric acid (p < 0.05) were due to the accelerated degradation of purine nucleotides. The rate of purine degradation including xanthine oxidase reactions characterizes the extent of an important radical source during oxygen deficiency, contributing to peroxidation of polyunsaturated fatty acids and the formation of peroxidation of polyunsaturated fatty acids and the formation of secondary aldehydic lipid peroxidation products.
Schmidt
H
H
Children's Hospital Singen, Germany.
Grune
T
T
Müller
R
R
Siems
W G
WG
Wauer
R R
RR
D000138:Acidosis / Q000378:metabolism; D000447:Aldehydes / Q000378:metabolism*; D001238:Asphyxia Neonatorum / Q000378:metabolism*; D016022:Case-Control Studies; D005312:Fetal Blood / Q000378:metabolism; D005865:Gestational Age; D005978:Glutathione / Q000031:analogs & derivatives / Q000097:blood*; D019803:Glutathione Disulfide; D006801:Humans; D019271:Hypoxanthine / Q000097:blood; D000860:Hypoxia / Q000378:metabolism*; D007231:Infant, Newborn; D015227:Lipid Peroxidation / Q000502:physiology*; D008315:Malondialdehyde / Q000378:metabolism*; D014527:Uric Acid / Q000097:blood
D000447:Aldehydes; D014527:Uric Acid; D019271:Hypoxanthine; D008315:Malondialdehyde; D005978:Glutathione; C027576:4-hydroxy-2-nonenal; D019803:Glutathione Disulfide